Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Beijing Tong Ren Tang Chinese Medicine Co ( (HK:3613) ) has provided an announcement.
Beijing Tong Ren Tang Chinese Medicine Company Limited has called its annual general meeting for 10 June 2026 in Hong Kong, where shareholders will vote on adopting the 2025 audited financial statements and related reports, and on the re-election of executive and independent non-executive directors with board-authorized remuneration. The agenda also includes approval of a final dividend of HK$0.37 per share and a special dividend of HK$0.03 per share for 2025, re-appointment of Ernst & Young as auditor, and a mandate allowing directors to issue up to 20% of the company’s share capital, excluding treasury shares, which could support future capital-raising and corporate flexibility.
These proposals, if passed, would affirm the existing governance structure and leadership while returning cash to investors through dividends, signaling management’s confidence in the company’s financial position. The renewed general mandate to issue additional shares, subject to defined limits and exceptions, positions the company to respond more nimbly to funding needs and potential growth opportunities, with implications for future capital structure and shareholder dilution.
More about Beijing Tong Ren Tang Chinese Medicine Co
Beijing Tong Ren Tang Chinese Medicine Company Limited is a Hong Kong–incorporated company engaged in the traditional Chinese medicine sector. Listed on the Stock Exchange of Hong Kong, it focuses on manufacturing and distributing Chinese medicinal products, serving both domestic and international healthcare markets.
Average Trading Volume: 1,046,715
Technical Sentiment Signal: Sell
Current Market Cap: HK$6.19B
Find detailed analytics on 3613 stock on TipRanks’ Stock Analysis page.